The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A marker-driven phase II trial of neoadjuvant chemotherapy in locally advanced colon cancer.
Anders Kristian Moeller Jakobsen
No relevant relationships to disclose
Fahimeh Andersen
No relevant relationships to disclose
Anders Fischer
No relevant relationships to disclose
Lars Henrik Jensen
No relevant relationships to disclose
Jens Christian Riis Joergensen
No relevant relationships to disclose
Ole Larsen
No relevant relationships to disclose
Jan Lindebjerg
No relevant relationships to disclose
John Ploeen
No relevant relationships to disclose
Soeren Rafael Rafaelsen
No relevant relationships to disclose
Jesper Vilandt
No relevant relationships to disclose